ArticleOncology letters2012
Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Identification of differentially expressed serum proteins in gastric adenocarcinoma.Journal of proteomics · 2015Trial
- SAA1 identified as a potential prediction biomarker for metastasis of hepatocellular carcinomaFrontiers in oncology · 2023Article
- SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma.Frontiers in neurology · 2022Article
- Identification and Validation of CYBB, CD86, and C3AR1 as the Key Genes Related to Macrophage Infiltration of Gastric Cancer.Frontiers in molecular biosciences · 2021Article
- SAA1 knockdown promotes the apoptosis of glioblastoma cells via downregulation of AKT signaling.Journal of Cancer · 2021Article
- Influence of gene expression on survival of clear cell renal cell carcinoma.Cancer medicine · 2020Article
- Validity of serum amyloid A and HMGB1 as biomarkers for early diagnosis of gastric cancer.Cancer management and research · 2020Article
- Serum amyloid A1 is upregulated in human glioblastoma.Journal of neuro-oncology · 2017Article
- Article
- Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study.Journal of translational medicine · 2015Article
- Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study.BMC complementary and alternative medicine · 2015Article
- Construction of protein profile classification model and screening of proteomic signature of acute leukemia.International journal of clinical and experimental pathology · 2014Article
- Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers.Cancer science · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to screen serum samples from gastric carcinoma patients and to determine whether serum amyloid A protein (SAA) served as a biomarker. SELDI technology was used to screen for changes in SAA levels in the serum samples. A mass cluster with a mass/charge (m/z) value between 11.1 and 11.9 kDa was identified in the serum samples from gastric carcinoma patients which was much higher than that of the control group. Furthermore, the increase in this m/z peak correlated with the severity of the cancer. High-performance liquid chromatography (HPLC) analysis confirmed that the peak was SAA1. In conclusion, this increase in SAA may be used as a potential biomarker for gastric cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.